Tocilizumab Prefilled Syringe ( DrugBank: Tocilizumab )

2 diseases

ID	Disease name (Link within this page)	Number of trials
41	Giant cell arteritis	1
46	Malignant rheumatoid arthritis	2

41. Giant cell arteritis

Clinical trials : 128 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04885829 (ClinicalTrials.gov)	May 31, 2021	3/5/2021	Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers	A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy Volunteers	Rheumatoid Arthritis;Giant Cell Arteritis	Drug: Tocilizumab Prefilled Syringe	Syneos Health	Dr. Reddy's Laboratories Limited	Recruiting	18 Years	50 Years	All	300	Phase 1	Australia;New Zealand

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04885829 (ClinicalTrials.gov)	May 31, 2021	3/5/2021	Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers	A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy Volunteers	Rheumatoid Arthritis;Giant Cell Arteritis	Drug: Tocilizumab Prefilled Syringe	Syneos Health	Dr. Reddy's Laboratories Limited	Recruiting	18 Years	50 Years	All	300	Phase 1	Australia;New Zealand
2	NCT03227419 (ClinicalTrials.gov)	January 22, 2018	19/7/2017	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders	Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial	Arthritis, Rheumatoid	Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe	Lille Catholic University	NULL	Recruiting	18 Years	N/A	All	224	Phase 4	France